{
  "model": "gemini-3-pro-preview",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gemini-3-pro-preview-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 138200,
  "agentCostUsd": 0.12475260000000002,
  "graderCostUsd": 0.0179375,
  "totalCostUsd": 0.14269010000000001,
  "agentUsage": {
    "promptTokens": 37173,
    "cachedTokens": 12983,
    "responseTokens": 2763,
    "thinkingTokens": 3385,
    "totalTokens": 43321
  },
  "graderUsage": {
    "promptTokens": 3738,
    "cachedTokens": 0,
    "responseTokens": 444,
    "thinkingTokens": 370,
    "totalTokens": 4552
  },
  "totalUsage": {
    "promptTokens": 40911,
    "cachedTokens": 12983,
    "responseTokens": 3207,
    "thinkingTokens": 3755,
    "totalTokens": 47873
  },
  "modelVersions": [
    "gemini-3-pro-preview"
  ],
  "agentFinalText": "I have completed the task.\n\nChecklist of written output files:\n- `output/study_overview.json`\n- `output/quantitative_findings.json`\n- `output/claim_audit.json`\n- `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral mRNA vaccination induce an interferon-rich state that sensitizes tumors to anti-PD-L1 immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice\",\n      \"description\": \"Tumor-bearing mice receiving intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice\",\n      \"description\": \"Tumor-bearing mice receiving vaccine only, ICI only, or vehicle, pooled across matched controls.\"\n    },\n    {\n      \"id\": \"human-retro\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens the MHC-I antigen repertoire.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"Mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The combination of intratumoral mRNA vaccine and anti-PD-L1 improves tumor control.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Type I interferon signaling is essential for the sensitization effect.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"Validation relies heavily on antibody-based blockade in mouse models.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better ICI outcomes in humans.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"Injecting mRNA Vaccines into Tumors May Boost Immunotherapy Effectiveness\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are drugs that help the immune system fight cancer, but they do not work for everyone. This study explores a new way to make these drugs more effective using mRNA vaccines—the same technology used for COVID-19 shots. Instead of preventing a virus, the researchers injected mRNA directly into tumors in mice. This injection acted like a 'fire alarm,' causing the tumor cells to produce stress signals called interferons. These signals made the tumor cells display more of their internal proteins on their surface, making them more visible to the immune system. When combined with standard immunotherapy drugs, this approach shrank tumors more effectively than drugs alone. The researchers also looked at past medical records of cancer patients and found that those who had received COVID-19 mRNA vaccines tended to respond better to immunotherapy, although this human data is preliminary and needs more rigorous testing to confirm a direct link. This research suggests that mRNA could be repurposed to turn 'cold' tumors 'hot,' making them susceptible to immune attack.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA delivery triggers an interferon response that widens the range of antigens presented by tumor cells.\",\n    \"Combining mRNA vaccination with anti-PD-L1 checkpoint blockade significantly improves tumor control in mouse models.\",\n    \"Retrospective data suggests a correlation between prior mRNA vaccination and better immunotherapy outcomes in cancer patients.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data is based on looking back at past records (retrospective), so unknown factors might explain the better outcomes.\",\n    \"Results in mice, especially using specific tumor models, do not always predict how the treatment will work in humans.\",\n    \"The timing of vaccination and the specific types of tumors treated varied widely among the patients studied.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immunotherapy\",\n      \"definition\": \"A type of cancer treatment that helps your immune system fight cancer.\"\n    },\n    {\n      \"term\": \"mRNA Vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to teach cells how to make a protein that triggers an immune response.\"\n    },\n    {\n      \"term\": \"Interferon\",\n      \"definition\": \"A protein released by animal cells, usually in response to the entry of a virus, that inhibits virus replication.\"\n    },\n    {\n      \"term\": \"Checkpoint Inhibitor\",\n      \"definition\": \"A drug that blocks proteins that stop the immune system from attacking cancer cells.\"\n    },\n    {\n      \"term\": \"Antigen\",\n      \"definition\": \"A toxin or other foreign substance that induces an immune response in the body, especially the production of antibodies.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will this combination therapy work for all types of cancer, or only specific ones?\",\n    \"What is the optimal timing and dosage for injecting the mRNA vaccine into the tumor?\",\n    \"Can the findings from the retrospective human study be confirmed in a randomized clinical trial?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-14T13:00:35.766Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-14T13:00:52.074Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-14T13:00:52.074Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-14T13:01:02.023Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-14T13:01:02.023Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-14T13:01:02.023Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-14T13:01:02.023Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-14T13:01:35.874Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-14T13:01:47.091Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-14T13:01:56.027Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-14T13:02:07.311Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 5,
        "coverage": 2,
        "usefulness": 5
      },
      "critical_issues": [
        "Study-design conflation in claim_audit.json (C02): it claims the intratumoral mRNA vaccine + anti-PD-L1 combination improves tumor control and cites the human survival p-value (L30) as supporting evidence. However, the human arm is a retrospective comparison by prior SARS‑CoV‑2 mRNA vaccination status under ICI (L15, L21-L24, L30), not intratumoral mRNA vaccination or a combination-therapy intervention in humans. Using L30 to support a claim about the intratumoral combination therapy is a material misinterpretation of what the human data represents.",
        "Overstated evidence strength label in claim_audit.json (C02): marking the combination claim as \"strong\" while partially relying on retrospective, non-randomized human association data (L30, with major confounding caveats in L49-L51) overstates the strength of evidence for clinical benefit of the specific intratumoral combination beyond mice (L46, L52, L55-L56).",
        "Ungrounded caveat in claim_audit.json (C03): the caveat \"Validation relies heavily on antibody-based blockade in mouse models\" is not stated in the provided report lines. While plausible, it is not grounded to a line reference and introduces an unsupported methodological characterization."
      ],
      "summary": "The study_overview.json and quantitative_findings.json largely mirror the report’s cohorts (L19-L24), quantitative metrics (L28-L33), and key controls (L36-L39). The public_summary.json is generally aligned and appropriately cautious about retrospective human data (L49-L51). However, claim_audit.json contains a major design/evidence mismatch: it uses the retrospective human survival association (L30) as evidence for efficacy of the intratumoral mRNA + anti-PD-L1 combination, even though the intr"
    }
  }
}
